EVERSANA Featured in NIH Study Detailing the Cost of Treating Rare Disease

“The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems”

EVERSANA™ was the only data and analytic organization invited by a consortium of provider organizations and the NIH to participate in a study with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS). The study, “The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems,” was published in the Orphanet Journal of Rare Diseases.

The study provides new evidence of the potential impact of rare diseases on public health, including the number of individuals with rare diseases and their medical costs being on par with cancer and heart failure.

EVERSANA’s data and analytics team, including Ramaa Nathan, PhD, EVERSANA Director of Data Science, and Pierantonio Russo, MD, Chief Medical Officer with EVERSANA’s Data & Analytics team, supported the study by providing data and analysis of patient journeys and associated costs.

Click here to read the full study.

EVERSANA’s data and analytics team, including Pierantonio Russo, MD, Chief Medical Officer with EVERSANA’s Data & Analytics team, Ramaa Nathan, PhD, EVERSANA Director of Data Science, and  and Alfonso Garbayo. VP, Business Development, attended the AHA 2022 Philadelphia Heart Ball.

 

 

 

 

 

 

 

 

 

 

 

 

Author
Pierantonio Russo, MD, FCPP, FAAP, STS
Chief Medical Officer, Data & Analytics

Dr. Russo has practiced cardiac and heart transplant surgery for over 20 years, and more recently he has been a healthcare executive with expertise in data and analytics, health economics and reimbursement, health insurance,…

Ramaa Nathan, PhD
Director, Data Science

Ramaa Nathan is a Director of Data Science at EVERSANA™ with several years of experience in the financial and healthcare industries. Ramaa is a data scientist and statistician with extensive programming, statistical and data…